Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Heartland Group Holdings (HGH) / HY22

NPAT +7.7% as lending growth lifts borrowings 32.6%

Underlying earnings progress is modest and clean, but a NZ$449m step-up in borrowings and deeply negative operating cash define the period.

Financials / Banking and finance

HGH revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $172.3m, versus $322.9m in FY25.

HGH Operating profit margin

Operating profit margin across covered periods.

↗
Loading chart...
HY26 was 45.2%, versus 36.8% in HY25.

HGH operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $299.5m, versus $673.2m in FY25.

HGH working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY24 was -$0.2m, versus $0.4m in FY23.
Release date
22 February 2022
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY22 vs HY21

Revenue

$130.8m

+8.9% ↑ vs $120.1m

Net profit after tax

$47.5m

+7.7% ↑ vs $44.1m

Net cash inflow from operating activities

−$142.3m

n/m ↓ vs −$5.3m

Interim dividend per share

5.5c

+37.5% ↑ vs 4.0c

Operating profit

$73.5m

+24.6% ↑ vs $59m

Cash and cash equivalents

$207.7m

+35.9% ↑ vs $152.8m

Total assets

$6b

+10.3% ↑ vs $5.4b

What changed

Heartland reported HY22 revenue (net operating income) of NZ$130.8m, up 8.9% on HY21, with PBT up 8.9% to NZ$64.9m and NPAT up 7.7% to NZ$47.5m

The headline progress is overshadowed by balance-sheet activity: gross borrowings rose 32.6% to NZ$1.8b and total assets grew 10.3% to NZ$6b, funding rapid loan-book expansion.

Operating cash outflow widened sharply from NZ$5.3m to NZ$142.3m, and pre-lease free cash flow of NZ$-150.9m is classified as an unprecedented low in Annolyse's historical baseline (4-period mean NZ$190.2m, range NZ$-25.5m to NZ$297.2m). Despite that, the interim dividend was lifted 37.5% to 5.5 cents per share.

Segment growth was concentrated in Australia (revenue +15.6%, derived margin 62.4% → 73.8%) and Reverse Mortgages (revenue +36.6%, share of group up 2.4pp), while Rural was flat and its result slipped from NZ$14.0m to NZ$13.1m.

What matters

The dominant capital event is balance-sheet expansion, not the P&L

Borrowings jumped NZ$448.5m in six months to fund finance-receivable growth, and the resulting NZ$142.3m operating cash outflow swamps the NZ$47.5m of profit. For a lender this pattern is normal when a book is growing, but it means current-period earnings are not the same thing as cash generated, and the equity base (NZ$778.2m, +5.6%) is supporting a materially larger asset stack.

Growth mix is shifting toward longer-duration and offshore assets. Reverse Mortgages and Australia together added share, with Australia's derived segment margin expanding more than 11 percentage points. That is the visible driver of group margin strength, but it also concentrates new exposure in two books whose credit and funding profiles differ from the legacy New Zealand business.

Dividend was raised against negative cash. Interim DPS rose 37.5% and payout to NPAT stepped up to 68.1% from 50.0% prior. Pre-lease FCF coverage is -21.4%, so the increase is being funded from wholesale and deposit growth rather than period cash – defensible while the loan book is profitable and growing, but a question if growth slows.

Expectations

No forward targets or guidance are supplied in the release

The only shape reference available is HY21, which represented 47.8% of FY21 revenue and 50.7% of FY21 NPAT, indicating a marginally second-half-weighted prior year. Annualising HY22 gives implied revenue near NZ$261.6m, which would extend the recent low-single-digit revenue-growth pattern in the historical baseline (4-period mean 7.3%).

What the release does not support is any read on credit-cost trajectory, funding mix, or net interest margin stability into 2H. Those gaps matter because the period's reported earnings growth sits on a balance sheet that has expanded much faster than equity.

Quality of result

The P&L itself is clean

PBT growth (+8.9%) is only 1.2 percentage points ahead of NPAT growth (+7.7%), the effective tax rate of 26.8% is close to the 26.1% prior, and ROE edged up to 6.1% from 6.0% – all within the supplied historical range. PBT margin of 49.6% is above Annolyse's historical baseline (4-period mean 32.0%, range 3.4%–47.9%), reflecting the Australia and Reverse Mortgage mix shift; durability depends on whether those segment margins hold as the books season.

The cash picture is the weak point, but it should be read as balance-sheet driven rather than earnings-quality driven. Capex was only NZ$8.6m (6.6% of revenue); the NZ$150.9m pre-lease FCF outflow is essentially the lending growth funded by the 32.6% rise in borrowings. The implication is that none of the reported NPAT was self-funded this period, and dividend cover relies on continued access to wholesale and depositor funding rather than on operating cash.

Unresolved

Open questions

What is the credit-quality trajectory across the loan book given the NZ$449m increase in borrowings deployed into lending growth?
How is the lending growth funded between wholesale facilities, retail deposits, and securitisation, and how sensitive is the net interest margin to that mix?
Why was the payout ratio lifted to 68.1% when pre-lease free cash flow was NZ$-150.9m?
What drove the Australia segment's derived margin expansion from 62.4% to 73.8%, and is it repeatable?
Will the Rural segment's lower current result reverse, or does it indicate a structural shift in that book?

This briefing cannot assess net interest margin, credit-impairment trends, funding-mix composition, or capital adequacy because those disclosures are not in the supplied extraction.

Chat

Ask about HGH HY22

Ask follow-up questions about Heartland Group Holdings's HY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about HGH HY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Heartland Group Holdings's HY22 result.

What is the credit-quality trajectory across the loan book given the NZ$449m increase in borrowings deployed into lending growth?Why does "The dominant capital event is balance-sheet expansion, not the P&L" matter?How strong was the cash and earnings quality in HY22?What should I watch next for HGH after HY22?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Heartland - 1H2022 Investor presentation

HY22 / results presentation↗

Heartland - 1H2022 Results Release

HY22 / results release↗

Heartland - HGH Financial statements

HY22 / financial report↗

Heartland - NZX Results Announcement (template form)

HY22 / results announcement↗

Prior comparable period

Heartland - 1H2021 Results Release

HY21 / results release↗

Heartland - HGH Financial statements

HY21 / financial report↗

Heartland - NZX Results Announcement (template form)

HY21 / results announcement↗

Full-year context

Heartland Group Holdings Financial Statements

FY21 / financial report↗

Heartland NZX Results Announcement Template

FY21 / results announcement↗

Heartland NZX Results Announcement Template

FY21 / results release↗

Release context

Heartland Annual Meeting to be held online only

HY22 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Dividend coverage and payout pressure

Dividend payout versus NPAT is 68.1%.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 1.2pp.

→

Revenue growth context

Revenue growth was 8.9% for this reporting period.

→

ROE and capital efficiency

ROE was 6.1%, +0.1pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when HGH publishes next

Get the next Heartland Group Holdings briefing and related NZX reporting-season updates by email.